Sarcopenic obesity (SO), a combination of excess fat and reduced muscle mass, is often missed due to reliance on body mass index. Current diagnostic methods frequently identify SO only after functional impairment develops.
Phenotypic Marker Assessment
Research explores using advanced imaging and molecular biology to detect early signs of the condition. The review examines phenotypic markers, including myosteatosis measured by computed tomography and the bioelectrical phase angle, assessing both muscle quantity and quality. It also investigates circulating biomarkers such as myokines, adipokines, inflammatory mediators, and emerging metabolomic, lipidomic, and microRNA signatures. These markers include myostatin, irisin, and the leptin-to-adiponectin ratio.
Framework for Early Detection
Integrating these phenotypic and circulating biomarkers offers a potential framework for precise risk characterization. This approach aims to facilitate earlier, individualized identification of SO. The framework is conceptual and requires standardization and prospective validation to ensure reliable results. This research highlights the importance of considering muscle health alongside fat mass when assessing an individual’s risk profile. The integration of multiple biomarkers represents a promising strategy for detecting SO before functional impairment occurs. In the context of pharmacological weight loss interventions, preserving muscle mass is becoming increasingly important. Further research is needed to establish standardized cut-offs for these molecular markers and to validate the proposed framework through prospective studies.